$2.97
0.34% today
Nasdaq, Apr 01, 07:17 pm CET
ISIN
US74587V1070
Symbol
PBYI
Sector
Industry

Puma Biotechnology, Inc. Stock price

$2.96
-0.62 17.32% 1M
+0.41 16.08% 6M
-0.09 2.95% YTD
-2.32 43.94% 1Y
+0.08 2.78% 3Y
-5.48 64.93% 5Y
-233.15 98.75% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.18 5.73%
ISIN
US74587V1070
Symbol
PBYI
Sector
Industry

Key metrics

Market capitalization $146.85m
Enterprise Value $119.96m
P/E (TTM) P/E ratio 4.85
EV/FCF (TTM) EV/FCF 3.09
EV/Sales (TTM) EV/Sales 0.52
P/S ratio (TTM) P/S ratio 0.64
P/B ratio (TTM) P/B ratio 1.58
Revenue growth (TTM) Revenue growth -2.19%
Revenue (TTM) Revenue $230.47m
EBIT (operating result TTM) EBIT $30.97m
Free Cash Flow (TTM) Free Cash Flow $38.86m
Cash position $100.97m
EPS (TTM) EPS $0.61
P/E forward 7.40
P/S forward 0.67
EV/Sales forward 0.55
Short interest 6.63%
Show more

Is Puma Biotechnology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Puma Biotechnology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Puma Biotechnology, Inc. forecast:

1x Buy
33%
1x Hold
33%
1x Sell
33%

Analyst Opinions

3 Analysts have issued a Puma Biotechnology, Inc. forecast:

Buy
33%
Hold
33%
Sell
33%

Financial data from Puma Biotechnology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
230 230
2% 2%
100%
- Direct Costs 64 64
3% 3%
28%
166 166
4% 4%
72%
- Selling and Administrative Expenses 69 69
12% 12%
30%
- Research and Development Expense 55 55
9% 9%
24%
42 42
5% 5%
18%
- Depreciation and Amortization 12 12
0% 0%
5%
EBIT (Operating Income) EBIT 31 31
7% 7%
13%
Net Profit 30 30
40% 40%
13%

In millions USD.

Don't miss a Thing! We will send you all news about Puma Biotechnology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Puma Biotechnology, Inc. Stock News

Positive
Seeking Alpha
one day ago
Puma SE is poised for a turnaround with strong growth plans in the US market and strategic athlete endorsements, leading me to assign a "Buy" recommendation. Despite recent subpar financial performance, Puma's robust dividend growth history and stable payout ratio indicate a solid foundation for future shareholder returns. My DCF analysis reveals that Puma is undervalued, with an intrinsic valu...
Neutral
Business Wire
6 days ago
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will present clinical data on its drug neratinib in a poster presentation on April 28 at the 2025 AACR Annual Meeting.
Positive
Seeking Alpha
11 days ago
Puma SE's stock has dropped nearly 50% year-to-date, with an additional 20% decline following its Q4 earnings, creating a potential value opportunity for long-term investors. Despite consistent revenue growth, Puma has struggled with profitability as rising operating expenses have outpaced sales, leading to stagnant net income over the past several years. High-profile collaborations with cultur...
More Puma Biotechnology, Inc. News

Company Profile

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Head office United States
CEO Alan Auerbach
Employees 172
Founded 2010
Website www.pumabiotechnology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today